Oncodrivers in Pleural Fluid for NSCLC with Malignant Pleural Effusion

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, non-randomized, cohort study conducted at regional pleural clinics. Researchers will measure PD-L1, ALK, and EGFR in pleural fluid samples from adults with NSCLC-related pleural effusion to determine the prevalence of oncodriver status. The analysis will also explore whether the amount of fluid tested affects the likelihood of detecting oncodrivers and how absence of these markers might influence subsequent diagnostic work-up. Follow-up occurs 8 weeks after enrollment to monitor initial clinical status. Eligible participants include adults with pleural effusion suspected or known to be associated with NSCLC, who can provide informed consent, excluding those without any oncodriver data available in current work-up or who cannot understand Danish.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Pleural effusion known or suspected of association with NSCLC (pleural fluid cytology positive for cells from NSCLC)
* Patients must be able to give informed consent

Exclusion Criteria:

* Full oncodriver status measured in any pleural fluid in current work-up
* Inability to understand written or spoken Danish.

Where it's running

• Næstved Sygehus, department of pulmonary medicine
  Næstved, Region Sjælland, Denmark Recruiting

Study contacts

• Study coordinator: Katrine Fjaellegaard, MD
• Email: kafj@regionsjaelland.dk
• Phone: 31924375

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.